Zoetis Inc. (NYSE:ZTS) Stock Has Consensus Target Price of $98.07

Shares of Zoetis Inc. (NYSE:ZTS) have been given a consensus rating of “Hold” by the nineteen brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $93.79.

Several equities research analysts have issued reports on ZTS shares. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. BTIG Research dropped coverage on shares of Zoetis in a research report on Friday. They issued a “buy” rating for the company. Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Stifel Nicolaus lowered their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. Finally, Piper Sandler dropped their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Price Performance

Shares of Zoetis stock opened at $79.67 on Monday. The stock has a market capitalization of $32.92 billion, a P/E ratio of 13.13, a PEG ratio of 1.18 and a beta of 0.67. The business has a 50 day simple moving average of $75.04 and a two-hundred day simple moving average of $93.64. Zoetis has a 12 month low of $68.77 and a 12 month high of $144.83. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company posted $1.76 earnings per share. The business’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts predict that Zoetis will post 6.15 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is currently 34.93%.

Institutional Trading of Zoetis

Several hedge funds have recently modified their holdings of ZTS. Guardian Wealth Management Inc. increased its position in shares of Zoetis by 8.5% in the 3rd quarter. Guardian Wealth Management Inc. now owns 69,586 shares of the company’s stock valued at $4,859,000 after purchasing an additional 5,462 shares during the last quarter. Ascent Group LLC raised its holdings in Zoetis by 31.7% during the third quarter. Ascent Group LLC now owns 14,310 shares of the company’s stock worth $999,000 after purchasing an additional 3,444 shares in the last quarter. Kelleher Financial Advisors raised its holdings in Zoetis by 239.2% during the third quarter. Kelleher Financial Advisors now owns 563 shares of the company’s stock worth $39,000 after purchasing an additional 397 shares in the last quarter. Markel Group Inc. lifted its position in shares of Zoetis by 542.5% during the 3rd quarter. Markel Group Inc. now owns 425,296 shares of the company’s stock worth $29,698,000 after buying an additional 359,101 shares during the last quarter. Finally, Parr Mcknight Wealth Management Group LLC lifted its position in shares of Zoetis by 9.2% during the 3rd quarter. Parr Mcknight Wealth Management Group LLC now owns 21,501 shares of the company’s stock worth $1,501,000 after buying an additional 1,811 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.